



BI02026 Delegate directory

QUEENSLAND
of OPPORTUNITY



Queensland
Government
Australia

Contents

Team Queensland at BIO 2026	2
Advancing global partnerships in life sciences	2
Our global footprint	2
Partner with Queensland to accelerate success in health and biomedical technology	3
Academic / medical research	4
Griffith University	4
QIMR Berghofer Medical Research Institute	4
Queensland University of Technology (QUT)	5
The University of Queensland (UQ)	5
Translational Research Institute (TRI)	6
UniQuest - University of Queensland (UQ)	7
University of the Sunshine Coast (UniSC)	7
Bioanalytical / laboratory services	8
360biolabs	8
Agilex Biolabs	8
Clinical trials – CROs, sites, technology	9
Alithia Life Sciences	9
Beyond Drug Development	9
Clinials	9
Momentum Clinical Research	10
My Medical Department	10
Novotech	12
Nucleus Network	12
Resolian	12
Southern Clinical Development Consulting (Southern CDC)	13
Thompson Brain & Mind Healthcare	13
Trialbeam	14
UniSC Clinical Trials	14
Economic development and government	15
Brisbane Economic Development Agency (BEDA)	15
Trade and Investment Queensland (TIQ)	15
Industry bodies	16
Life Sciences Queensland (LSQ)	16

Innovation precincts and incubators	16
ARM Hub	16
Boggo Road Innovation Junction (BRIJ)	16
Gold Coast Health & Knowledge Precinct (GCHKP)	17
Solutions for Manufacturing Advanced Regenerative Therapies (SMART)	
Cooperative Research Centre (CRC)	17
Investors/investment advisory	20
Altea Investments	20
OneVentures	20
Manufacturing / bioprocessing	21
Cytiva	21
Thermo Fisher Scientific	21
Watson-Marlow Pty Ltd	22
Service providers	22
Acclime	22
Davies Collison Cave	22
Graythan Regulatory Services	23
Griffith Hack	23
Prime Financial	24
James & Wells	24
KE Select	24
Larkfield	25
MBIP	25
MinterEllison	25
PSC Biotech	26
Rob McInnes IP Advisory	26
Thomsons	26
Start-ups / biotechs	27
DatChem Pty Ltd	27
Foxo Technology Pty Ltd	27
Gelomics	28
LTR Pharma Ltd	28
Macrobiome Therapeutics	28
MassAffinity	29
Microbio	29
Proseek Bio	30
QBiotics	30
RoboFit	30

Team Queensland at BIO 2026: Advancing global partnerships in life sciences

Trade and Investment Queensland (TIQ) and the Department of State Development, Infrastructure and Planning (DSDIP) are proud to lead Team Queensland at BIO 2026 in San Diego, showcasing one of the world's fastest-growing and most collaborative life sciences ecosystems. Our delegation brings together representatives from Queensland's world-class life sciences and biotechnology sector, highlighting expertise across research, development, clinical trials, advanced therapeutics, digital health, and commercialization.

Queensland is internationally recognized for its strong translational research capabilities, globally competitive clinical trial environment, advanced manufacturing infrastructure, and growing biotechnology sector. Supported by leading universities, research institutes, hospitals, and innovation precincts, the state offers a highly connected ecosystem for companies and partners seeking to accelerate discovery, investment, and global market expansion across the Asia-Pacific region.

BIO 2026 provides a powerful platform to foster international collaboration, attract investment, and position Queensland as a premier destination for biotechnology innovation, precision medicine, and global life sciences growth.

Our global footprint

Trade and Investment Queensland's international network connects Queensland businesses and research organisations with key markets across North America, Europe, the Middle East, and Asia-Pacific. With representatives located in major commercial and innovation hubs worldwide, Queensland offers partners direct access to market insights, investment opportunities, industry connections, and in-market support.

This global presence supports collaboration across biotechnology, health innovation, clinical trials, advanced manufacturing, and research translation - helping organisations build partnerships, expand internationally, and access new growth opportunities.

Partner
with Queensland
to accelerate success
in health and biomedical
technology.



Academic / medical research

Griffith University

Griffith University is a leading Australian research university with strengths across life sciences, biotechnology, and medtech spanning drug discovery, vaccines, diagnostics, medical devices and clinical research.

With leading research and translation institutes such as the Institute for Biomedicine and Glycomics, Griffith Clinical Trials Unit, Compounds Australia, PRECISE, and the Gold Coast Health and Knowledge Precinct the university, through Griffith Enterprise, partners with industry to translate research into commercial and real-world health impact through licensing, clinical trials, contract research and strategic partnerships.

Eloise Keeffe	Business Manager (Commercial)	e.keeffe@griffith.edu.au
Dr Mark Ashton	Director, Griffith Enterprise	m.ashton@griffith.edu.au
Ujjwal Dua	Head of Business & Innovation, Life Sciences	u.dua@griffith.edu.au

QIMR Berghofer Medical Research Institute

QIMR Berghofer is a Queensland Government statutory authority and Australia's leading independent medical research institute with bench to bedside solutions and translational strengths in cancer, infectious diseases, chronic disorders, precision medicine, cellular therapy manufacturing and gene therapy. It is home to 1,000+ scientists, staff and students across 67 laboratories, supported by world-class infrastructure including GMP-accredited cell therapy manufacturing, PC3 containment labs, and NATA-accredited platforms for flow cytometry, imaging and histology, with over \$50M in core facilities. The Institute hosts 110 PhD students from 28 countries and delivers 100+ scientific events annually. It partners with government, global biotech and pharma, and research organisations to accelerate translation and deliver new therapies, while strengthening sovereign biomanufacturing capability and enabling coordinated investment across Australia's biomedical sector.

Dr Balaji Somasundaram	General Manager, Q-Gen Cell Therapeutics	balaji.somasundaram@qimrb.edu.au
Dr Dale Pavlovski	Head of Commercial Services	dale.pavlovski@qimrb.edu.au
Prof Grant Ramm	Director and CEO	Grant.Ramm@qimrb.edu.au

Dr Robert McLachlan	Chief Commercial Officer	robert.mclachlan@qimrb.edu.au
Dr Shea Carter	Head of Innovation and Translation	shea.carter@qimrb.edu.au
Dr Balaji Somasundaram	General Manager, Q-Gen Cell Therapeutics	balaji.somasundaram@qimrb.edu.au
Tamanna Monem	Head of Growth and Partnerships	tamanna.monem@qimrb.edu.au

Queensland University of Technology (QUT)

QUT combines leading biomedical research with a strong translation track record, reflected in its “university for the real world” ethos. Strengths span microbiome science, medical technologies, AI-enabled health, bioinformatics, and core biomedical fields including immunology, cancer, and genomics. Its microbiome work is unlocking previously uncultivable organisms, supported by scale-up capability and GMP manufacturing pathways. Medical technology research integrates engineering, biological, and clinical expertise to deliver solutions such as cardiac pumps, 3D-printed scaffolds, and organ-on-chip platforms. Nationally leading vision science complements this portfolio. These capabilities sit within a highly connected clinical ecosystem across Queensland’s major precincts, enabling efficient progression from discovery to patient and commercial impact.

Kate Taylor	Director, Industry Engagement	kate.taylor@qut.edu.au
-------------	-------------------------------	------------------------

The University of Queensland (UQ)

The University of Queensland (UQ) is consistently ranked among the world’s top 50 universities and one of Australia’s leading teaching and research universities.

UQ is at the cutting edge of biomedical advancements, providing solutions to some of the world’s biggest health challenges. Their impact lies in our deep relationships and collaborations with some of the world’s leading therapeutic and medical device companies, as well as Queensland, Australian and international governments. Some of our most successful partnerships are with companies including Stryker, Sanofi, Merck & Co, Novartis, Pfizer, Telix and our own start-up companies including Vicebio, Vaxxas, Inflazome, Infensa Biosciences and Protagonist Inc.

Chris Pugmire	Head of Business Development	c.pugmire@uq.edu.au
---------------	------------------------------	---------------------

Dr Felicia Kolonjari	Senior Business Development Officer	f.kolonjari@uq.edu.au
Dr Julia Hocking	Associate Director, Health and Biomedical Science	j.hocking@uq.edu.au
Dr Lisette Pregelj	Deputy Director Biotechnology Program	lisette.pregelj@uq.edu.au
Mike Brennan	Associate Director - Defence, Space & National Security	michael.brennan@uq.edu.au
Shravan Singh	Director, Strategic Partnerships, Government and Industry	shravan.singh@uq.edu.au
Prof Timothy Mercer	Professor	t.mercer@uq.edu.au

Translational Research Institute (TRI)

Located within the Boggo Road Innovation Junction (BRIJ), a rapidly growing biomedical innovation cluster integrating manufacturing, research, clinical and commercial capabilities to accelerate clinical translation and product commercialisation, the Translational Research Institute (TRI) offers world-class facilities that integrates research, preclinical, clinical trial and manufacturing capabilities.

Part of the TRI, ENTRI supports companies seeking ready-to-use cGMP cleanrooms, incl. wet labs and office space. From clinical to commercial supply, ENTRI provides scalable cGMP infrastructure to enable manufacturing across a range of products.

Supported services include equipment procurement and qualification, quality and regulatory activities, person-in-plant, workforce development, and more traditional CDMO-style support as you build local teams and scale operations.

Luke Fairburn	Industry and Commercial Operations Manager	luke.fairburn@tri.edu.au
Dr Ryan Parlett	Head of Commercial Operations	ryan.parlett@tri.edu.au

UniQuest - University of Queensland (UQ)

UniQuest transforms world-class research into solutions that matter, bridging academic excellence and commercial success. With deep technical expertise and market insight, it unlocks the full potential of The University of Queensland's intellectual property.

Its track record includes the blockbuster cervical cancer vaccine Gardasil and startup companies Spinifex Pharmaceuticals and Inflazome, both among the largest university startup exits in Australian history. In 2025, Sanofi acquired UQ vaccine company Vicebio for US\$1.15 billion upfront, with potential milestone payments of up to US\$450 million, the largest deal involving IP from an Australian university.

Dr Craig Belcher	Head of Life Sciences	c.belcher@uniquet.com.au
David Markwell	Senior Director, Commercialisation - Life Sciences	d.markwell@uniquet.com.au
Dr Stephen Earl	Senior Director, Therapeutic Acceleration - Life Sciences	s.earl@uniquet.com.au
Dr Tamsin Terry	Senior Director, Commercialisation - Life Sciences	t.terry@uniquet.com.au

University of the Sunshine Coast (UniSC)

The University of the Sunshine Coast is Australia's youngest greenfield university and will turn 30 in 2026. The University has almost 18,000 students, including 500 postgraduate research students across five campuses. Five Schools and seven research Institutes and Centres are dedicated to healthy people, improving the quality of human life and a healthy planet, improving the quality of our environment. UniSC has a longstanding commitment to sustainability from campus design to international reforestation research programs. Our health related research is largely undertaken in the UniSC Clinical Trials Centre, Thompson Institute, the Centre for Bioinnovation and the School of Health.

Lucas Litewka	Director	llitewka@usc.edu.au
---------------	----------	---------------------

Bioanalytical / laboratory services

360biolabs

360biolabs is Australia's most comprehensive bioanalytical laboratory, offering an extensive range of pharmacokinetic and pharmacodynamic endpoints to support a diverse range of modalities and therapeutic areas under quality systems including GLP, GCLP and ISO17025. Global assay transfer to our US or EU labs under harmonised SOPs for continuity of bioanalytical excellence for studies post Phase 1.

Angela Luttick

Executive Vice President, Commercial

angela.luttick@360biolabs.com

Agilex Biolabs

Agilex Biolabs is an FDA-inspected bioanalytical laboratory, supporting biotech and pharmaceutical companies from preclinical through to late-stage clinical development. Agilex delivers high-quality pharmacokinetic, biomarker, immunogenicity, flow cytometry, and cell-based assay services across a broad range of therapeutic modalities, supporting more than 160 projects annually. With facilities across Adelaide, Sydney, and Brisbane - Agilex is purpose-built to support fast-moving early-phase clinical trials through rapid turnaround times and collaborative project delivery.

Ricky Matias

Senior Business Development Director

ricky.matias@agilexbiolabs.com

Clinical trials – CROs, sites, technology

Alithia Life Sciences

Australian-owned boutique full-service Contract Research Organisation (CRO) supporting pharmaceutical, biotechnology, medical device and institutional research organisations across Phase I-III clinical development programs.

Dr Jovana Milosevic	Chief Commercial Officer	jovana.milosevic@alithialifesciences.com
A/Prof Tina Soulis	Founder and Director	tina.soulis@alithialifesciences.com

Beyond Drug Development

Beyond is a privately owned product development consultancy and early phase Contract Research Organization (CRO) located in Australia, specializing in supporting small to medium biotech and pharmaceutical companies worldwide. Beyond's expertise spans from preclinical drug development, with the assistance of our regulatory and preclinical experts, to progressing into clinical stages and "Beyond."

Amelia Beshara	Co-Founder	amelia.beshara@beyonddrugdev.com
Louise Moore	Co-Founder and Director	louise.moore@beyonddrugdev.com

Clinials

Clinials is a Protocol Intelligence platform that turns complex clinical trial protocols into structured outputs including schedules of activities, lab listings, esource Case Report Forms and patient-facing materials enabling trial teams to reduce manual effort, stay aligned to the protocol, and start studies faster with greater accuracy.

Maree Beare	CEO	maree.beare@clinials.com +1(469)9833888
-------------	-----	--------------------------------------------

Momentum Clinical Research

Momentum Clinical Research is the region's largest full phase clinical trial network with 18 sites across New Zealand and Australia. With over two decades of experience, 200+ investigators and a participant database exceeding 200,000, we deliver end-to-end Phase I-IV clinical trials across a broad range of therapeutic areas.

Designed to simplify and accelerate study delivery, our fully centralised model provides sponsors with a single point of contact across feasibility, start-up, recruitment and delivery removing fragmentation and reducing timelines.


Josh Stent	CEO	josh.stent@momentumclinicalresearch.com
Kacey Murphy	Chief Commercial Officer	kacey.murphy@momcr.co.nz

My Medical Department

My Medical Department is a physician-led global medical consultancy/CRO with teams based in the UK and Australia. Their highly experienced Physicians, Pharmacists and Scientists provide clients with the unique advantage of round-the-clock medical expertise. Ensuring seamless support across time zones.

Services span clinical development, regulatory affairs, pharmacovigilance and safety, and medical affairs to support programs from early-phase trials through to market readiness and ongoing commercial success.

Kwesi Ackah	Global Director of Strategic Development	kwesi@mymedicaldepartment.com
-------------	------------------------------------------	-------------------------------



Novotech

Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.

Gina Paine	Business Development Manager	Communications@novotech-cro.com
------------	------------------------------	---------------------------------

Nucleus Network

Nucleus Network is a leading global provider of early-phase clinical trials, operating specialized Phase I units across Australia, the United States, and the United Kingdom. It is the only multi-site, multi-country early-phase organization offering streamlined access to all major regulatory markets through one network. With more than 2,500 early-phase studies and over 1,500 First-in-Human trials completed, Nucleus Network is recognized for scientific expertise and operational excellence. Its facilities, housing more than 350 Phase I beds, are co-located within major medical precincts, enabling rapid recruitment from a volunteer database exceeding 700,000 participants.

Chris Hickey	Chief Business Development Officer	c.hickey@nucleusnetwork.com +1 (443) 685-5800
--------------	------------------------------------	--------------------------------------------------

Resolian

Resolian is a global contract research organization (CRO) supporting pharmaceutical and biotech companies with specialized bioanalytical and analytical sciences solutions. Over 500 experts across the U.S., U.K., China, and Australia deliver quality results, ensuring the highest standard of regulatory compliance throughout the drug development continuum.

Resolian's specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, drug metabolism/pharmacokinetics (DMPK), and CMC analytical and materials science. Dedicated laboratories equipped with state-of-the-art technology meet the needs of preclinical and clinical programs at any scale.

Dr. Rob Stachlewitz	CEO	
---------------------	-----	--

Dr Ryan Klein	VP, Business Development	rklein@resolian.com
---------------	--------------------------	---------------------

Southern Clinical Development Consulting (Southern CDC)

Southern Clinical Development Consulting (Southern CDC) is an Australian clinical research organisation dedicated to advancing therapeutic development and improving patient outcomes.

Southern CDC operates as an end-to-end clinical development partner, combining deep, cross-therapeutic scientific expertise with boutique-level accountability, providing the strategic insight of an internal team with the capability of a full-service CRO. We support sponsors across the full development continuum, from non-clinical strategy through to clinical execution and commercialisation, integrating seamlessly as an extension of the sponsor team to accelerate trials and bring new therapies to patients faster.

Simone Flight, PhD RAC	Head of Regulatory Affairs	sflight@southerncdc.com +61 421 515 326
------------------------	----------------------------	--------------------------------------------

Thompson Brain & Mind Healthcare

Thompson Brain & Mind Healthcare (TBMH) is a privately backed precision psychiatry and neuroinnovation company translating next-generation mental health science into scalable clinical and commercial outcomes.

TBMH operates a vertically integrated platform combining clinical services, advanced diagnostics, clinical trials, and research and development under one roof. This model provides direct access to large, characterisable patient cohorts, enabling rapid recruitment, high-quality data generation, and efficient trial execution.

TBMH partner with global sponsors, research institutions, and industry to design, deliver, and de-risk clinical trials across CNS, psychiatric, and emerging therapeutic domains, including psychedelic-assisted therapies. Our platform integrates biomarker-driven protocols, AI-enabled decision support, and digital endpoints to enhance signal detection, reduce timelines, and improve probability of success.

Brady Sullivan	Head of Commercial Strategy & Partnerships	bsullivan@tbmh.org.au
Chris Le Serve	Managing Partner, TBMH Commercial	cleserve@tbmh.org.au
Professor Jim Lagopoulos	Executive Director and CEO	jlagopoulos@tbmh.org.au

Trialbeam

Clinical Trial recruitment intelligence

Sanja Marais	Co-Founder and CEO	sanja@trialbeam.ai
--------------	--------------------	--------------------

UniSC Clinical Trials

UniSC Clinical Trials is a university based multi-site clinical trial network across South East Queensland combining academic rigor with operational agility. Specialising in delivering high-quality and efficient industry sponsored studies, from first-in-human, healthy volunteer through to late phase trials in patient populations, we combine priority with passion to ensure operational excellence and improve access to innovative research within our community. With 40+ beds across our network, we collaborate with pharmaceutical and biotechnology companies to support their development by conducting both high-volume trials and specialised, complex studies across a broad portfolio of therapeutic areas.

Dr Tom Bailey	Associate Director	tbailey@usc.edu.au
Tom Nott	Senior Business Development Manager	tnott@usc.edu.au

Economic development and government

Brisbane Economic Development Agency (BEDA)

Brisbane, the capital city of Queensland, is a fast-growing economy in Australia (\$275BN by 2041) boasting a health ecosystem that is a 'go to' destination for clinical trials, commercialization and export led growth, underwritten by a \$18BN health infrastructure pipeline.

Brisbane Economic Development Agency (BEDA) drives investment demand for Brisbane, by working with government and private sector organizations, providing full market entry service, to support global investors to leverage opportunities within the city.

Lisa Cavallaro	Senior Manager - Investment	lcavallaro@brisbane-eda.com.au
----------------	-----------------------------	--------------------------------

Trade and Investment Queensland (TIQ)

Trade and Investment Queensland (TIQ) is the Queensland Government's dedicated global business agency for international investment and trade, with global teams based in 27 locations across 18 international markets, and eight regional Queensland locations.

TIQ connects Queensland to the world and the world to Queensland – driving global business opportunities.

Alita Singer	Director, Investment (NYC)	alita.singer@tiq.qld.gov.au +1 646 530 4418
Andrew Letton	Director, Investment (Defense and Aerospace)	andrew.letton@tiq.qld.gov.au +1 415 470 1704
Gabe Sulkes	A/Deputy Commissioner	Gabe.Sulkes@tiq.qld.gov.au +1 415 310 1817
Patti Terando	Operations Manager	patti.terando@tiq.qld.gov.au +1 415 407 0981

Industry bodies

Life Sciences Queensland (LSQ)

Life Sciences Queensland Limited (LSQ) serves as Queensland's peak body for the life sciences sector, fostering collaboration among industry stakeholders and the life sciences community to drive business growth and innovation. LSQ aims to provide a pivotal role in creating a dynamic, globally competitive, and sustainable life sciences industry in the state.

Samuel Jesuadian	Board Director	samuel.jesuadian@armhub.com.au
Prof Trent Munro	Board Director	t.munro@uq.edu.au

Innovation precincts and incubators

ARM Hub

ARM Hub is Queensland's independent, not-for-profit centre for advanced robotics, AI, and design-led manufacturing, headquartered in Brisbane. Established with Queensland Government backing and anchored by a founding partnership with QUT and Urban Art Projects, ARM Hub bridge the gap between cutting-edge research and real-world industry impact.

Samuel Jesuadian	Chief Commercial Officer	samuel.jesuadian@armhub.com.au
------------------	--------------------------	--------------------------------

Boggo Road Innovation Junction (BRIJ)

BRIJ is Brisbane's 39-hectare innovation hub advancing breakthroughs at the intersection of human health and planetary wellbeing.

BRIJ's 13,000+ researchers, clinicians and entrepreneurs deliver global impact, from life-saving vaccines and advanced therapeutics to breakthroughs in sustainable agriculture and climate resilience. World-renowned institutions collaborate here across biomedical development, clinical translation, environmental research, agricultural technologies and enabling fields like AI and quantum computing.

Prof Trent Munro	General Manager	trent@brijj.au
------------------	-----------------	----------------

Gold Coast Health & Knowledge Precinct (GCHKP)

The Gold Coast Health & Knowledge Precinct (GCHKP) is one of Australia's fastest-growing innovation districts, designed to accelerate the translation of scientific discovery into real-world health solutions. Anchored by Griffith University and the major clinical infrastructure of Gold Coast University Hospital and Gold Coast Private Hospital, the GCHKP brings together leading researchers, clinicians, and industry partners to advance breakthroughs in biotechnology, genomics, diagnostics, and advanced therapeutics.

Aaron Isted	Senior Manager	a.isted@griffith.edu.au
-------------	----------------	-------------------------


Solutions for Manufacturing Advanced Regenerative Therapies (SMART) Cooperative Research Centre (CRC)

SMART CRC (Solutions for Manufacturing Advanced Regenerative Therapies Cooperative Research Centre) is a national industry-led collaboration advancing the scalable manufacture and commercial translation of regenerative therapies, bringing together expertise across cell and gene therapies, bioprocessing, GMP manufacturing, clinical translation, regulatory pathways and workforce development. Through partnerships spanning industry, research and healthcare, SMART CRC is building integrated capabilities to support the development, manufacture and delivery of next-generation therapies for cancer, cardiovascular disease, arthritis and other chronic and age-related conditions, strengthening Australia's role in the global regenerative medicine and advanced therapeutics ecosystem.

Isaac Coonan	Chief Development Officer	i.coonan@smartcrc.com.au
Dr Leanna Read	Chair	l.read@smartcrc.com.au
Dr Sarah Costanzo	Chief Operating Officer	s.costanzo@smartcrc.com.au
Prof Simon Cool	CEO	s.cool@smartcrc.com.au



Collaborate with
Queensland's abundant
natural wealth to drive
biomedical innovation.



Investors/investment advisory

Altea Investments

Altea Investments is Hillhouse's Asia-Pacific life sciences real estate platform, developed through Rava Partners. We develop, own, and operate purpose-built science and innovation assets alongside leading universities, research institutions, and industry partners. Our edge lies in proprietary access to Hillhouse's investment network - spanning life sciences, deep-tech venture, frontier energy, and advanced industrials - giving us real-time visibility into where global research demand is heading. Active across Australia, Singapore, and India, with Japan and South Korea on the horizon, Altea combines institutional real estate capability with scientific operating expertise to deliver environments that attract talent, accelerate discovery, and create long-term value.

Olivia Geng

Executive Director Strategic Partnerships and Innovation

ogeng@alteainvestments.com

OneVentures

OneVentures is one of Australia's leading venture capital firms, scaling technology and healthcare companies through growth equity and credit. Since 2010 OneVentures has launched 7 funds and manage over AU\$1 billion. They do more than invest. They take companies to their next stage by actively shaping their future, applying years of international experience and hands-on operational capability to accelerate growth across the portfolio.

OneVenture's healthcare pillar backs biomedical companies across therapeutics and medtech, moving promising assets through their key value-inflection milestones. Portfolio companies include BiVACOR, whose total artificial heart is in first-in-human studies, and Vaxxas, developing needle-free vaccine delivery. We back transformative technology that delivers best-in-class patient outcomes with global reach and impact.

Sarah Meibusch

Partner, Head of Healthcare

smeibusch@one-ventures.com

Manufacturing / bioprocessing

Cytiva

Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. They bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients. We're the provider of leading life science brands such as ÄKTA, Amersham, HyClone, MabSelect and Whatman.

Nicolas Pichon

Key Account Manager

nicolas.pichon@cytiva.com
+61 400 692 926

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over \$40 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them.

Their end-to-end, integrated CDMO services help biotechnology, pharmaceutical, and life sciences companies with their drug development and manufacturing journeys. From research and development to regulatory landscape support, supply chain management, and everywhere in between, our services and solutions support the entire life cycle of drug substances and drug products, from preclinical research to commercial manufacturing.

Majella Clifton

Director Business Management -
Europe & Asia Pacific

majella.clifton@thermofisher.com

Watson-Marlow Pty Ltd

Watson-Marlow Fluid Technology Solutions (WMFTS) is a global engineering and manufacturing company specialising in precision fluid management technologies for regulated life science environments.

Supporting pharmaceutical, biotechnology and medical device sectors, WMFTS provides peristaltic pumps, single-use fluid path assemblies, aseptic filling systems and containment solutions for bioprocessing, sterile fill-finish and advanced therapeutics manufacturing, enabling scalable, GMP-compliant production from R&D through to commercial manufacture.

Behzad Molavi	Life Science Sector Manager, ANZ	behzad.molavi@wmfts.com
---------------	----------------------------------	-------------------------

Service providers

Acclime

Acclime is a global corporate services and advisory firm that supports international biotech and life sciences companies establishing and operating R&D activities in Australia. Acclime provides an integrated, end-to-end service covering entity setup, tax structuring, resident directors and public officers, accounting, payroll and ongoing statutory compliance, allowing offshore R&D teams to operate seamlessly from day one.

David Brown	President, US and Head of Partnerships, Americas	d.brown@acclime.com
Luis Silva	Business Development Manager	l.silva@acclime.com

Davies Collison Cave

Leading intellectual property law firm specialising in patents, trademarks and commercial IP strategy for life sciences and technology sectors.

Dr Simone Vink	Principal	svink@dcc.com
Dr Tania Uren	Principal	turen@dcc.com

Graythan Regulatory Services

GRS is a Brisbane-based regulatory affairs consultancy specialising in pharmaceuticals, biotechnology, cell and gene therapies, biologics, ATMPs, and medical devices. Since 2017, GRS has supported more than 60% of Australia's commercial GMO licences.

GRS operates one of Australia's first privately owned Institutional Biosafety Committees (IBC), providing governance, secretariat, and OGTR compliance support for GMO programmes. Clinical services include CTN/CTA management, GCP compliance, HREC submissions, and Trial Master File oversight.

GRS also provides Local Entity and Australian Director Support, helping international sponsors establish a compliant Australian presence and access the Federal R&D Tax Incentive.

Barbara Kienast	Head of Clinical Operations & Regulatory Affairs	Barbara.Kienast@graythanregulatoryservices.com
Mark Reid	CEO	Mark.Reid@graythanregulatoryservices.com

Griffith Hack

Griffith Hack is a leading Australian intellectual property firm with more than 120 years' experience helping businesses, research institutions and innovators protect and maximise the value of their IP. With offices in Melbourne, Sydney, Brisbane and Perth, and a team of over 130 professionals, including patent and trade mark attorneys and lawyers, Griffith Hack supports clients ranging from startups to Fortune 500 companies.

Chris Vindurampulle	Principal	chris.vindurampulle@griffithhack.com
Malcolm Lyons	Principal	malcolm.lyons@griffithhack.com

Prime Financial

Prime Financial Group (ASX: PFG) provides full-service accounting and tax support to life sciences companies conducting R&D activities in Australia. The firm specialises in helping international biotech and pharmaceutical sponsors access non-dilutive funding through the Australian R&D Tax Incentive, which offers cash rebates on eligible research and clinical development expenditure.

Prime supports clients across the full lifecycle of their Australian operations, including entity setup, ongoing financial management, and preparation of R&D Tax Incentive applications.

George Zafiris	Associate	georgez@primefinancial.com.au
----------------	-----------	-------------------------------

James & Wells

Since 1979, James & Wells has been at the forefront of biotechnology innovation in Australasia, assisting clients grow, leverage and protect their IP, drawing on deep experience managing large portfolios for international corporations, safeguarding start-up ideas, and everything in between.

Specialties include immunology, gene therapy, drug development, antibody therapeutics, cell therapies, vaccines and diagnostics.

Dr Andrew Clarke	Partner	andrew.clarke@jamesandwells.com
------------------	---------	---------------------------------

KE Select

KE Select is an Australian-based, leading Biotechnology & Medical Technology Recruitment Partner for many organizations within the Life Science, Clinical Trial, GMP Manufacturing and Healthcare space.

Evelyn Parker	Director of Partnerships	evelyn@keselect.com
Kerry McMahon	CEO	kerry@keselect.com

Larkfield

Larkfield Consulting is a boutique advisory firm, with an office in Arizona, specializing in the commercialization and strategic growth of biotechnology and life sciences ventures, with expertise spanning artificial intelligence and autonomous systems.

Kate Gunn	Founder and CEO	kategunn@larkfieldconsult.com
-----------	-----------------	-------------------------------

MBIP

MBIP are an independent Australian intellectual property firm specialising in patent and trade mark law, with established offices in Brisbane and Melbourne, serving inventors, entrepreneurs, research institutions, and corporations both locally and internationally.

Dr David Tso	Principal	david@mbip.com.au
--------------	-----------	-------------------

MinterEllison

MinterEllison is Australia's leading independent law firm, with a Band 1 Chambers-ranked life sciences practice advising across medical research, biotechnology, pharmaceuticals and medical devices. Our integrated team supports clients across the full lifecycle, from discovery and clinical development to commercialisation and global expansion. We deliver coordinated advice across regulatory, clinical trials, intellectual property, data and digital, commercial, capital and M&A, tax and disputes. We combine technical excellence with commercial insight to help clients navigate complexity, unlock growth and bring innovative therapies to market.

Sonja Read	Partner	sonja.read@minterellison.com
------------	---------	------------------------------

PSC Biotech

PSC Biotech Australia is part of PSC Biotech®, a global life sciences consultancy specialising in validation, regulatory compliance, quality assurance, and technology solutions for regulated industries. The company supports pharmaceutical, biotechnology, medical device, and advanced therapy organisations to navigate complex growth while maintaining compliance with global standards.

In Australia, PSC Biotech provides services including commissioning, qualification and validation (CQV), quality management systems, auditing, regulatory affairs, and computer system validation. Backed by global expertise in electronic quality management systems (eQMS) and compliance, the team helps organisations achieve operational excellence and maintain inspection readiness across the product lifecycle.

Megan Scally	Business Operations Manager	mscally@biotech.com
Samuel O'Callaghan	Managing Director	socallaghan@biotech.com

Rob McInnes IP Advisory

Rob specialises in IP transactions, and advises clients on the management and commercialisation of IP rights. His work mainly involves planning, negotiating and structuring licence agreements and R&D contracts, and conducting diligence on new technology ventures. Currently Rob is shifting his focus away from legal work and towards angel investing, training, mentoring and board and advisory committee roles.

Rob McInnes	Principal	rob@robmcinnes.com.au
-------------	-----------	-----------------------

Thomsons

Thomsons is a major Australian corporate and commercial law firm operating out of Sydney, Melbourne, Brisbane, Perth, Adelaide and Canberra.

They are the 8th largest law firm partnership in Australia with over 925 people and 155 partners, with a full service offering for corporate and commercial work and offer best practice specialist skills and experience across a number of areas and sectors including Biotechnology and Pharmaceuticals, Capital Markets, Mergers and Acquisitions, Competition and Regulation, Health, Intellectual Property, Technology Commercialisation, Technology and Telecommunications, Litigation and Dispute Resolution and Tax.

Katrina Chambers	Partner	kchambers@thomsons.com.au +61 497 210 127
------------------	---------	----------------------------------------------

Start-ups / biotechs

DatChem Pty Ltd

DatChem is a SaaS medical technology company using proprietary magnetic resonance analytics to deliver rapid clinical insights in under four minutes.

DatChem-Breast identified breast cancer risk up to a decade earlier than standard imaging following a 12-year longitudinal clinical study. DatChem-Neuro provides an objective diagnosis, and response to therapy, for PTSD, blast overpressure and ADHD. LOI signed with Siemens.

Dr Carolyn Mountford

Co-Founder and CEO

carolyn.mountford@datchem.life

Foxo Technology Pty Ltd

Foxo's cloud-based intelligence platform replaces fragmented, outdated communication tools to help build the health relationship layer. Foxo's latest innovation reduces access barriers with a two-way communication delivered from a carepass in the patient's phone digital wallet - no app required. Foxo's footprint has expanded from diagnostic imaging and pathology into clinical trials - positioning Foxo at the nexus of digital health and biotech. Foxo is a Microsoft ISV partner, a Texas Medical Center HealthTech Accelerator company, and won the 2024 Rice Alliance BioHouston Award as a Most Promising Life Science company.

Mani Sahihi

Co-Founder & CEO

mani@foxo.com

Gelomics

Gelomics is a biotechnology company developing advanced New Approach Methodologies (NAMs) to improve the predictive power and ethical standards of preclinical drug development. The company has created an integrated technology platform combining engineered biomaterials, laboratory devices, and artificial intelligence to enable researchers to grow realistic 3D human microtissues in vitro.

Dr Christoph Meinert

CEO

christoph.meinert@gelomics.com

LTR Pharma Ltd

Clinical-stage pharmaceutical company developing innovative therapies focused on rapid-onset drug delivery technologies. LTR Pharma's lead product, SPONTAN[®], is an intranasal treatment for erectile dysfunction designed to provide a faster onset of action than conventional oral therapies. The company leverages proprietary nasal delivery platforms to address unmet patient needs and improve treatment adherence.

Headquartered in Australia, LTR Pharma is advancing its clinical development pipeline and pursuing regulatory pathways to commercialise novel therapies in sexual health and other indications.

Lee Rodne

Executive Chairman

lrodne@ltrmedical.com

Macrobiome Therapeutics

Macrobiome Therapeutics is developing a novel class of biologic therapies for inflammatory bowel disease (IBD) by harnessing immune-regulating mechanisms evolved through millions of years of co-existence between humans and hookworms. The company is translating naturally occurring hookworm-derived proteins into safe, targeted therapeutics designed to restore immune balance and reduce chronic inflammation without the risks associated with live parasite therapies. By combining advanced protein engineering with insights from evolutionary biology, Macrobiome aims to deliver first-in-class treatments for ulcerative colitis, Crohn's disease, and other immune-mediated disorders, addressing significant unmet needs in gastrointestinal health.

Prof Alex Loukas

Founder and Chief Scientific Officer

alex.loukas@macrobiometherapeutics.com

Dr Keats Nelms

CEO

keats.nelms@macrobiometherapeutics.com

MassAffinity

MassAffinity is a drug discovery platform company advancing next-generation therapeutics for complex biological targets. Our platform integrates native mass spectrometry, advanced target engagement and proteomics technologies to enable the discovery and mechanistic characterization of novel small molecules, molecular glues and peptides across a broad range of therapeutic areas.

Alongside development of our internal pipeline in women's health (Endometriosis), we actively collaborate with biotechnology companies, pharmaceutical partners and academic groups through flexible discovery, co-development and strategic partnering models with a particular focus on challenging or previously intractable targets.

Tamara Mills	CEO	t.mills@massaffinity.com
--------------	-----	--------------------------

Microbio

Microbio is a biotechnology company based in Brisbane, Australia and specialised in the development and manufacturing of innovative diagnostic tools. The team at Microbio has brought together the latest advances in bioinformatics, genomics and molecular microbiology to develop a unique and revolutionary pathogen identification test.

Focused on infectious diseases, the company is working tirelessly to deliver its game-changing technology to millions of patients who will benefit from faster, more accurate pathogen diagnosis and improved treatment outcomes.

Dr Flavia Huygens	Chief Scientific Officer, Founder and Executive Director	fhuygens@microbio.com.au
-------------------	----------------------------------------------------------	--------------------------

Proseek Bio

Proseek Bio is a Brisbane-based biotechnology startup developing next-generation blood diagnostics for women's health, with an initial focus on ovarian cancer.

Founded in 2023 by Michelle Hill, the company translates glycoproteomics research into clinically deployable tests that improve early detection and patient triage.

Proseek Bio's lead product, OC-Triage, is designed to support pre-surgical assessment of ovarian cancer risk.

Dr Leo Bolero	Co-Founder and Chief Commercial Officer	leo@proseek.bio +61 468 730 037
---------------	-----------------------------------------	------------------------------------

QBiotics


QBiotics is an Australian biotech company developing novel anti-cancer and wound healing therapeutics derived from the epoxitiglianes platform. Its lead oncology candidate, tigilanol tiglate is currently involved in 3 Phase II clinical trials for head and neck cancer, soft tissue sarcoma and breast cancer, is approved for veterinary oncology (Stelfonta®) in multiple international markets. Based in Queensland, QBiotics collaborates with research, clinical and commercial partners to advance translational oncology and biotechnology innovation.

Ebru Davidson	Interim CEO and Managing Director	ebru.davidson@qbiotics.com
---------------	-----------------------------------	----------------------------

RoboFit

RoboFit focuses on supporting individuals with neurological conditions to explore what's possible with new and emerging technologies including neuro controlled exoskeletons. At the core of their mission is to focus on harnessing neuroplasticity to help people improve their independence.

Maryanne Harris	Co-Founder	maryanne@robofit.com.au
-----------------	------------	-------------------------





Connect with us today



TIQ TRADE +
INVESTMENT
QUEENSLAND

[TIQ.QLD.GOV.AU](https://tiq.qld.gov.au)